Trevena Inc TRVN

$0.00 +0.00 (25.00%)

Valuation

Market cap: 0
Revenue TTM: $3,130,000
Net income TTM: $-40,290,000
P/E (trailing): 0.00
P/E (forward): —
Profit margin: -1,287.22%
Debt to equity: -1.41

Trading

Volume: 900
Avg volume: 774
Day's range: $0.00 – $0.00
Shares out: 959,000
Stochastic %K: 0%
Beta: -1.83
Analysts: —
Price target: $5.00

Price

Company profile

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 610 354 8840
Website: https://www.trevena.com
Address: 955 Chesterbrook Boulevard, Suite 110, Chesterbrook, United States